Use of antineoplastic agents in patients with cancer who have HIV/AIDS

Research output: Contribution to journalReview articlepeer-review

Abstract

Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.

Original languageEnglish (US)
Pages (from-to)905-912
Number of pages8
JournalThe Lancet Oncology
Volume12
Issue number9
DOIs
StatePublished - Sep 2011

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Use of antineoplastic agents in patients with cancer who have HIV/AIDS'. Together they form a unique fingerprint.

Cite this